Online inquiry

IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1804MR)

This product GTTS-WQ1804MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1804MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7734MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ12377MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ12940MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ14049MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ9208MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ9779MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ6476MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ12286MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW